Jobs
-
Almirall has licensed European rights to aclidinium bromide, both as a monotherapy and in combination with formoterol to Italian pharmaceutical company Menarini. The agreement covers most of the EU except for the UK, the Netherlands… Read more . . .
-
After spurning repeated offers from Valeant, ISTA Pharmaceuticals has agreed to be acquired by Bausch + Lomb for $9.10 per share in cash, a total of about $500 million. Valeant had offered $7.50 per share.… Read more . . .
-
The FDA has issued a complete response letter to MAP Pharmaceuticals’ NDA for Levadex dihydroergotamine inhalation aerosol for the treatment of migraine headaches. According to MAP, “the FDA requested that the Company address issues relating… Read more . . .
-
A Massachusetts engineering firm called Enginasion has disclosed details of proprietary DPI-filling technology it says that it developed for a pharmaceutical client that needed accurate dispensing of a highly cohesive inhaled dry powder formulation into… Read more . . .
-
According to Teva, the FDA has approved its QNASL HFA beclomethasone dipropionate nasal aerosol for the treatment of seasonal and perennial allergic rhinitis in adults and children 12 years of age and older, and the… Read more . . .
-
Almirall has published full results from the ATTAIN (Aclidinium To Treat Airway obstruction In COPD patieNts) study in The European Respiratory Journal (ERJ). ATTAIN was a six-month double-blind placebo-controlled study that compared two doses of… Read more . . .
-
According to GlaxoSmithKline and Theravance, the two companies have now completed all studies for the Relovair fluticasone furoate (FF)/vilanterol (VI) DPI for both COPD and asthma, and they plan to move forward now with regulatory… Read more . . .
-
OINDP testing specialist NextBreath has successfully completed an evaluation by the World Health Organization (WHO) Performance Quality System (PQS) as a testing facility for nasal spray vaccine administration. The company is now accredited to perform… Read more . . .
-
Belgian biopharmaceutical company Ablynx has announced that Boehringer Ingelheim will extend funding for discovery, development, and commercialization of Ablynx’s Nanobody therapeutics for an additional two years, until September 2014. One of the Ablynx programs ALX-0171,… Read more . . .
-
Meda has announced that its Astepro azelastine nasal spray for the treatment of allergic rhinitis has received registration approval in Europe through the centralized procedure and that it will now begin the national registration processes… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK